Tiziana life sciences announces positive clinical results in the second patient with secondary progressive multiple sclerosis (spms) following three months of dosing with intranasal foralumab

New york, june 08, 2022 (globe newswire) -- tiziana life sciences (nasdaq: tlsa) ("tiziana" or the "company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug administration, today reported positive clinical results from the second patient with secondary progressive multiple sclerosis (spms) in the ongoing study as part of an expanded access program at the brigham and women's hospital (bwh), boston, ma. these results confirm the previously reported data, from the first spms patient after three months of treatment of the first spms patient. the treatment with foralumab, a fully human anti-cd3 monoclonal antibody, was well-tolerated and improved clinical and pet imaging analyses.
TLSA Ratings Summary
TLSA Quant Ranking